Trevi Therapeutics, Inc. Interest Expense
Trevi Therapeutics, Inc. (TRVI) reported Interest Expense of $1.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-08
- Trevi Therapeutics, Inc. interest expense for the quarter ending 2024-06-30 was $1.00K, a 99.35% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $1.00K, a 99.57% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $4.00K, a 98.54% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $3.00K, a 98.97% decline year-over-year.
- Trevi Therapeutics, Inc. interest expense for fiscal 2023 was $391.00K, a 66.38% decline from fiscal 2022.
- Trevi Therapeutics, Inc. interest expense for fiscal 2022 was $1.16M, a 3.24% decline from fiscal 2021.
- Trevi Therapeutics, Inc. interest expense for fiscal 2021 was $1.20M, a 163.60% increase from fiscal 2020.
- Trevi Therapeutics, Inc. interest expense for fiscal 2020 was $456.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-08 | $2.00K 10-Q · filed 2024-08-08 | $6.00K derived: sum of 3 quarters · filed 2024-08-08 | $9.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $1.00K 10-Q · filed 2024-05-07 | $5.00K derived: sum of 2 quarters · filed 2024-05-07 | $8.00K derived: sum of 3 quarters · filed 2024-05-07 | $161.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $7.00K derived: sum of 2 quarters · filed 2024-03-20 | $160.00K derived: sum of 3 quarters · filed 2024-08-08 | $391.00K 10-K · filed 2024-03-20 |
| 2023-09-30 | $3.00K 10-Q · filed 2023-11-09 | $156.00K derived: sum of 2 quarters · filed 2024-08-08 | $387.00K 10-Q · filed 2023-11-09 | $661.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $153.00K 10-Q · filed 2024-08-08 | $384.00K 10-Q · filed 2024-08-08 | $658.00K derived: sum of 3 quarters · filed 2024-08-08 | $950.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $231.00K 10-Q · filed 2024-05-07 | $505.00K derived: sum of 2 quarters · filed 2024-05-07 | $797.00K derived: sum of 3 quarters · filed 2024-05-07 | $1.09M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $566.00K derived: sum of 2 quarters · filed 2024-03-20 | $861.00K derived: sum of 3 quarters · filed 2024-03-20 | $1.16M 10-K · filed 2024-03-20 |
| 2022-09-30 | $292.00K 10-Q · filed 2023-11-09 | $587.00K derived: sum of 2 quarters · filed 2023-11-09 | $889.00K 10-Q · filed 2023-11-09 | $1.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $295.00K 10-Q · filed 2023-08-10 | $597.00K 10-Q · filed 2023-08-10 | $906.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.21M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $302.00K 10-Q · filed 2023-05-11 | $611.00K derived: sum of 2 quarters · filed 2023-05-11 | $914.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.21M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $612.00K derived: sum of 2 quarters · filed 2023-03-16 | $908.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.20M 10-K · filed 2023-03-16 |
| 2021-09-30 | $303.00K 10-Q · filed 2022-11-10 | $599.00K derived: sum of 2 quarters · filed 2022-11-10 | $893.00K 10-Q · filed 2022-11-10 | $1.20M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $296.00K 10-Q · filed 2022-08-11 | $590.00K 10-Q · filed 2022-08-11 | $898.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.05M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $294.00K 10-Q · filed 2022-05-12 | $602.00K derived: sum of 2 quarters · filed 2022-05-12 | $750.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $456.00K derived: sum of 2 quarters · filed 2022-03-17 | $456.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $148.00K 10-Q · filed 2021-11-10 | $148.00K 10-Q · filed 2021-11-10 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $0.00 derived: sum of 2 quarters · filed 2020-03-16 | $51.00K derived: sum of 3 quarters · filed 2020-03-16 | $174.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $51.00K derived: sum of 2 quarters · filed 2019-11-14 | $174.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $51.00K 10-Q · filed 2019-08-12 | $174.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $123.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |